Tom de la Bastide is the Global Co-Head of Finance and a partner in the Paul, Weiss Finance Group. He focuses on financings for leveraged buyouts, alternative lending transactions for hedge funds, mezzanine funds, banks and other lenders, corporate debt issuances for Fortune 500 companies and complex debt restructurings.
Working with clients across a broad spectrum of financing transactions, de la Bastide represents major corporations, financial institutions, hedge funds and private equity sponsors in their acquisition financings, secured and unsecured bank financings, mezzanine financings, second-lien financings, asset-based loans, restructurings and DIP and exit facilities.
He advises clients in domestic and international lending transactions, including acquisitions, divestitures, structured financings, restructurings and derivative products. De la Bastide also has experience in junior capital lending transactions, intercreditor issues and secured creditor and bankruptcy rights. His clients represent a variety of industries, including consumer products, manufacturing, media and entertainment, apparel, food and beverage, publishing, oil and gas, automotive and technology.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2027 Lawdragon 500 Leading Dealmakers | 2027 | Corporate Finance |
| The 2026 Lawdragon 500 Leading Dealmakers in America | 2026 | Corporate Finance |
| The 2025 Lawdragon 500 Leading Dealmakers in America | 2025 | Corporate Finance |
| The 2024 Lawdragon 500 Leading Dealmakers in America | 2024 | Corporate Finance |
| The 2022 Lawdragon 500 Leading Dealmakers in America | 2022 | Corporate Finance |
| Lawdragon 500 Leading Dealmakers in America | 2021 | Corporate Finance |
Some of de la Bastide’s private equity and funds representations include:
- The Carlyle Group in the financing aspects of its acquisition of Content Partners, and in Content Partners’ subsequent acquisition of a portfolio of interests in 200 films and several hundred episodes of television
- Florida Cancer Specialists & Research Institute, LLC (FCS) in the approximately $2.5 billion all-cash sale of a 70% stake in its internal business and administrative services arm, Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), to McKesson Corporation
- The Chatterjee Group in numerous transactions, including alongside private equity firm Rhone Group and Illuminate Buyer in connection with $1.3 billion in credit facilities to fund a portion of the acquisition of McDermott International Inc.’s Lummus Technology Group
- PCI Pharma in its $4 billion refinancing
- Additional representative clients include Centerbridge Partners, GP Investments, KPS Capital Partners, Pamplona Capital
Some of de la Bastide’s public company representations include:
- Bioverativ in the financing aspects of its $11.6 billion acquisition by Sanofi
- Elanco Animal Health in the $5 billion senior secured credit facilities in connection with the acquisition of Bayer Animal Health
- Encana Corp. in the financing aspects of its $7.7 billion acquisition of Newfield Exploration Company
- Michael Kors in numerous transactions, including the financing aspects of its $1.35 billion acquisition of Jimmy Choo and over $1 billion in credit facilities
- Revlon in its $1.83 billion term loan financing, successful out-of-court exchange offer, two exit financing facilities: (i) a $1.4 million term loan facility and (ii) a $325 million asset-based revolving facility, and multiple refinancings
Some of de la Bastide’s corporate reorganization, private credit and refinancing representations include:
- Charlesbank Capital Partners as arranger and lender under a $350 million first lien term loan facility with the parent company of FullBeauty. The facility will refinance and replace certain term loans incurred by FullBeauty upon its exit from its 2019 pre-arranged bankruptcy
- Towerbrook Capital Partners in the successful out-of-court restructuring of its portfolio company J.Jill